Executive Summary

Pfizer has outsourced part of its medical sales in China in an attempt to cut costs and push its non-core products. NovaMed Pharmaceuticals will exclusively distribute and promote Pfizer's six tumor drugs, namely, Adriamycin, Daunorubicin, Leucovorin, Methotrexate, Estracyt and Farlutal from June, to increase the hospital coverage rate for the drugs by 30 percent to 40 percent. Novamed has developed an entire tumor drug product line and established broad-ranging relationships with tumor drug distributors across the nation. In addition, the company participates in hospital drug tenders and drug pricing, with plans to introduce more MNC tumor drugs to China. This unique model shows that pharmaceutical MNCs are leveraging on outsourcing to penetrate the country's distribution network. (Click here for more - Chinese Language)